Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68001-472

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68001-472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 01)

Chemical structure diagram of Divalproex Sodium, showing its molecular composition and arrangement of atoms including carbon, hydrogen, oxygen, and sodium elements in a repeating polymeric form.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 02)

A bar chart comparing two studies measuring percentages for placebo (PBO) and Divalproex Sodium (DVPX). Study 1 shows approximately 26% for PBO and 60% for DVPX, while Study 2 shows roughly 29% for PBO and 58% for DVPX. The y-axis denotes percentage values from 0% to 70%.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 03)

A cumulative response curve chart comparing Divalproex Sodium and placebo, showing the percentage reduction in CPS rate versus percentage of patients. The vertical axis represents improvement or worsening in CPS rate, and the horizontal axis shows the percentage of patients, with curves depicting better reduction for Divalproex Sodium versus placebo.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 04)

A cumulative distribution graph comparing patients' improvement in CPS rate by high dose and low dose treatments of Divalproex Sodium. The x-axis shows the percentage of patients, and the y-axis shows the percentage reduction in CPS rate, with improvement indicated upwards and worsening downwards.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 05)

A bar chart comparing two studies on the effects of Placebo versus Divalproex Sodium. The vertical axis shows a numeric scale from 0 to 7, with bars indicating a higher value for Placebo compared to Divalproex Sodium in both Study 1 and Study 2.*

FDA Label Image

Divalproex 125mg (39cef9df 868d 4963 B0a7 7f146275442f 07)

Label for Divalproex Sodium Delayed Release Tablets, USP 125 mg by BluePoint Laboratories. The label specifies the tablet strength as 125 mg of valproic acid activity, with a package containing 100 tablets. It advises storage at controlled room temperature (20° to 25°C) and includes manufacturer information: Unichem Laboratories Ltd., India, for BluePoint Laboratories.*

FDA Label Image

Divalproex 250mg (39cef9df 868d 4963 B0a7 7f146275442f 08)

Label for Divalproex Sodium Delayed Release Tablets USP, 250 mg, oral tablets with valproic acid activity. The label indicates storage instructions and pharmacist guidance. Manufactured by Unichem Laboratories Ltd. and labeled for BluePoint Laboratories. The package contains 100 tablets.*

FDA Label Image

Divalproex 500mg (39cef9df 868d 4963 B0a7 7f146275442f 09)

Label for Divalproex Sodium Delayed Release Tablets, USP 500 mg by BluePoint Laboratories. The label notes valproic acid activity and includes storage instructions, barcode, NDC 68001-474-00, and states the package contains 100 tablets. Manufactured by Unichem Laboratories Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.